The Overall Cost of Glaucoma Treatment:

Focus on Generic Treatments May Increase Cost

Supported by an educational grant from Allergan, Inc.

As the American population continues to age, glaucoma is projected to affect 3.4 million Americans by 2020 and 4 million by 2030. While the average expenditure per patient per year is low relative to other disease states, the cumulative direct medical costs are currently $2.9 billion and are projected to increase prevalently. Healthcare organizations will no longer be able to ignore patients with glaucoma and rely solely on generic medications for cost savings. This monograph is designed to provide managed care leaders with the foundation they need to understand patients with glaucoma and explore the value of vision to patients and to payors, offering insight into the range of available treatments, and discussing methods of analyzing treatments for cost-efficiency across populations.

The goal of this enduring educational activity is to provide managed care leaders the tools to design analytical methods of determining coverage policies for glaucoma treatment for their healthcare plan’s specific populations, resulting in excellent visual outcomes for glaucoma patients in the most cost-efficient manner.

This activity is designed for managed care medical directors who treat and manage patients with glaucoma. No prerequisites required.

After completing this activity, the participant will demonstrate the ability to:
  • DISCUSS the value attached to vision and visual quality of life for patients.
  • COMPARE the indications, mechanism of action, and efficacy and safety data on current and emerging glaucoma therapies.
  • DESCRIBE the impact adherence has on the long-term costs of glaucoma management.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Advanced Studies in Medicine (ASiM) and the National Association of Managed Care Physicians (NAMCP). NAMCP is accredited by the ACCME to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The estimated time to complete this activity: 120 minutes.

Release date: August 10, 2015.        Expiration date: August 10, 2016.

Gary M. Owens, MD (Course Director)
Gary Owens Associates
Past VP, Medical Management and Policy
Independence Blue Cross
Ocean View, Delaware

Eve J. Higginbotham, SM, MD
Vice Dean, Inclusion and Diversity
Senior Fellow, Leonard Davis Institute of Health Economics
Professor of Ophthalmology
Scheie Eye Institute
Philadelphia, Pennsylvania

Daniel A. Lace, MD, CPE, FACPE
Chief Medical Officer at Leaders in Medicine, Inc
Chicago, Illinois

Gary M. Owens, MD, has no real or perceived financial relationships to disclose.
Daniel A. Lace, MD, CPE, FACPE, has no real or perceived financial relationships to disclose.
Eve J. Higginbotham, SM, MD, has no real or perceived financial relationships to disclose.

Planning Committee:
Katie Eads has no real or perceived financial relationships to disclose.
Lisa Mangione has no real or perceived financial relationships to disclose.
Christina Ohnsman, MD, reports serving on a speakers’ bureau for Alcon Laboratories, Inc.

NAMCP, ASiM, and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

Please complete a brief, unaccredited pre-assessment before reading this monograph. After reading this monograph, participants may receive credit by completing the CME test and evaluation online, and receiving a score of 70% or higher. A certificate of participation will be available online immediately following successful completion of the activity.


Managed Care Perspectives on the Overall Cost of Glaucoma Treatment:
    Does Focusing on Generic Treatments Increase Costs?

Gary M. Owens, MD

Current and Emerging Treatment Strategies in Open-Angle Glaucoma
Eve J. Higginbotham, SM, MD

Managed Care Considerations in the Treatment of Glaucoma
Daniel A. Lace, MD, CPE, FACPE


Submit a case to review at meeting:

procced to pretest

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us